Amlodipine/rosuvastatin/telmisartan - Jeil Pharmaceutical

Drug Profile

Amlodipine/rosuvastatin/telmisartan - Jeil Pharmaceutical

Alternative Names: JLP-1401

Latest Information Update: 28 Oct 2016

Price : $50

At a glance

  • Originator Jeil Pharmaceutical
  • Class Antihyperlipidaemics; Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Fluorobenzenes; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action ACE inhibitors; Angiotensin type 1 receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Cardiovascular disorders

Most Recent Events

  • 28 Oct 2016 Chemical structure information added
  • 21 Mar 2016 Phase-III clinical trials in Cardiovascular disorders in South Korea (PO) prior to March 2016 (Jeil Pharmaceutical's pipeline, March 2016)
  • 01 Feb 2015 Phase-I clinical trials in Hypertension (In volunteers) in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top